These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 16949914)

  • 1. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
    Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
    Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
    Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
    Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
    Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
    Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy.
    Anatelli F; Chuang ST; Yang XJ; Wang HL
    Am J Clin Pathol; 2008 Aug; 130(2):219-23. PubMed ID: 18628090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
    Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
    Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
    Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
    Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
    Nassar A; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
    Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.
    Baumhoer D; Tornillo L; Stadlmann S; Roncalli M; Diamantis EK; Terracciano LM
    Am J Clin Pathol; 2008 Jun; 129(6):899-906. PubMed ID: 18480006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
    Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
    Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
    Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH
    Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more.
    Kandil DH; Cooper K
    Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of Glypican-3 expression in hepatocellular carcinoma but downregulation in cholangiocarcinoma indicates its differential diagnosis value in primary liver cancers.
    Man XB; Tang L; Zhang BH; Li SJ; Qiu XH; Wu MC; Wang HY
    Liver Int; 2005 Oct; 25(5):962-6. PubMed ID: 16162153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
    Tátrai P
    Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma.
    Ushiku T; Shinozaki A; Shibahara J; Iwasaki Y; Tateishi Y; Funata N; Fukayama M
    Am J Surg Pathol; 2010 Apr; 34(4):533-40. PubMed ID: 20182341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
    Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE
    Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
    Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z
    Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
    Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
    Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
    Esheba GE; Pate LL; Longacre TA
    Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
    Llovet JM; Chen Y; Wurmbach E; Roayaie S; Fiel MI; Schwartz M; Thung SN; Khitrov G; Zhang W; Villanueva A; Battiston C; Mazzaferro V; Bruix J; Waxman S; Friedman SL
    Gastroenterology; 2006 Dec; 131(6):1758-67. PubMed ID: 17087938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.